Molecular Profiling Institute and Specialty Laboratories Launch CardioEvaluatR™ Testing Program
Complete the form below to unlock access to ALL audio articles.
The Molecular Profiling Institute and Specialty Laboratories have announced that they are now providing the CardioEvaluatR™ advanced cardiovascular testing program for patients nationwide.
The CardioEvaluatR program connects advanced comprehensive testing to scientifically reference clinical guidelines to track and address cardiovascular disease.
The scope of this program and the associated guidelines are developed and updated by a board of expert preventive and interventional cardiologists including Dr. Robert Superko, Chairman of Molecular, Genetic and Preventive Cardiology at the Fuqua Heart Center of Atlanta; Dr. Arthur Agatston of South Beach Cardiology; Dr. Spencer King III, Fuqua Chair of Interventional Cardiology; Dr. P.K. Shah, Director of the Division of Cardiology and the Atherosclerosis Research Center at Cedars-Sinai Medical Center, Los Angeles; and Dr. Robert Roberts, CEO of the Ottawa Heart Institute, Ottawa, Canada.
"The CardioEvaluatR program provides valuable information to physicians and patients faced with the challenges of atherosclerosis who are seeking more detailed analytical information on the present nature of their disease," notes Dr. Spencer King III, Fuqua Chair of Interventional Cardiology and past President of the American College of Cardiology.
"From 'laboratory bench to bedside,' the mission of the CardioEvaluatR program is to translate the latest research to help improve clinical outcomes and patient management in the field of cardiovascular medicine" Dr King III said.
"CardioEvaluatR is a critical diagnostic tool to support the new paradigm of preventive cardiovascular care," said Dr. Agatston of South Beach Cardiology, developer of the Agatston calcium score and author of The South Beach Diet and The South Beach Heart Program.
The CardioEvaluatR program utilizes the infrastructure and esoteric testing capabilities of the Molecular Profiling Institute, Phoenix, AZ and Specialty Laboratories, Valencia, CA.
The first phase of the CardioEvaluatR program involves the release of three advanced testing panels that incorporate a high density lipoprotein (HDL) sub-classification technology developed by Agilent Technologies, Santa Clara, CA, licensed to the Molecular Profiling Institute. HDL subclass analysis is gathering significant momentum in the field of cardiology as an emerging marker in the identification of cardiovascular disease risk and treatment decisions.
"This is an exciting time for the Molecular Profiling Institute and Specialty Laboratories," said Dr. Robert Penny, Chairman and CEO of the Molecular Profiling Institute. "We have integrated the appropriate technology and have engaged a world-class advisory team so that we may better address cardiovascular disease."
